You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Mallinckrodt
Colorcon
McKinsey

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR POTIGA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for POTIGA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02149836 Study to Treat Major Depressive Disorder (MDD) With a New Medication Completed Icahn School of Medicine at Mount Sinai Phase 2 2014-08-01 The purpose of this study is to test the antidepressant effects of Ezogabine in major depressive disorder (MDD). The investigators also aim to determine the safety and tolerability Ezogabine in patients with MDD. The investigators hypothesize that depressive symptoms will be significantly decreased following an 8-week treatment period of the medication compared to baseline.
NCT02450552 Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Recruiting ALS Association Phase 2 2015-06-01 This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT02450552 Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Recruiting GlaxoSmithKline Phase 2 2015-06-01 This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT02450552 Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Recruiting Harvard University Phase 2 2015-06-01 This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT02450552 Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Recruiting Massachusetts General Hospital Phase 2 2015-06-01 This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT02450552 Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Recruiting Brian Wainger Phase 2 2015-06-01 This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT03043560 Study to Treat Major Depressive Disorder With a New Medication Recruiting Baylor College of Medicine Phase 2 2017-09-25 This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure disorders).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for POTIGA

Condition Name

Condition Name for POTIGA
Intervention Trials
Major Depressive Disorder 1
Depressive Disorder 1
Depression 1
Anhedonia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for POTIGA
Intervention Trials
Disease 2
Depressive Disorder 2
Depression 2
Depressive Disorder, Major 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for POTIGA

Trials by Country

Trials by Country for POTIGA
Location Trials
United States 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for POTIGA
Location Trials
New York 3
Texas 1
Pennsylvania 1
North Carolina 1
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for POTIGA

Clinical Trial Phase

Clinical Trial Phase for POTIGA
Clinical Trial Phase Trials
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for POTIGA
Clinical Trial Phase Trials
Recruiting 2
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for POTIGA

Sponsor Name

Sponsor Name for POTIGA
Sponsor Trials
Harvard University 1
GlaxoSmithKline 1
James Murrough 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for POTIGA
Sponsor Trials
Other 7
Industry 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Dow
Moodys
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.